KNSA
Kiniksa Pharmaceuticals, Ltd.
NASDAQ · Healthcare · Biotechnology · BM
$77.91
−3.18%Margins
Gross margin
54.5%
EBITDA margin
13.3%
EBIT margin
11.9%
Net margin
9.6%
FCF margin
21.8%
12.3%
Return on equity
9.0%
Return on assets
15.1%
Return on invested capital
0.98x
Asset turnover
$185.2M
Cash from operations
$6.74
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026